Articles

CDK6 may be a useful biomarker in patients with estrogen receptor–positive breast cancer who develop acquired resistance to CDK4/6 inhibitors, and inhibition of the PI3K/Akt/mTOR pathway may be a reasonable therapeutic approach for these patients. Read More ›

The new oral selective estrogen receptor degrader (SERD) elacestrant demonstrates potent antitumor activity in in vitro models, with additive effects to CDK4/6 inhibitors. Read More ›

Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer. Read More ›

Dr Matthew Goetz believes that, as more mature data come into existence, the demonstration of a survival advantage will guide more patients with metastatic breast cancer to try CDK4/6 inhibitors plus aromatase inhibitors instead of chemotherapy. Read More ›

Dr Matthew Goetz addresses common questions that arise when patients with HER+ metastatic breast cancer have progressed on a CDK4/6 inhibitor plus an aromatase inhibitor. Read More ›

This cost-per-responder analysis of patients treated on the MONARCH trial showed that sarilumab was more economically dominant compared with adalimumab with respect to incremental costs per response for patients with active, moderate-to-severe rheumatoid arthritis (RA).

Read More ›

A large multidatabase, population-representative cohort study showed a similar risk for primary composite cardiovascular events between patients with rheumatoid arthritis (RA) who newly started tocilizumab and abatacept starters. Read More ›

Results from a systematic review and network meta-analysis of randomized controlled trials showed that tofacitinib 10 mg and baricitinib 8 mg combined with methotrexate were both effective in patients with rheumatoid arthritis (RA), with similar safety outcomes. Read More ›

A real-world analysis of electronic health record (EHR) databases across Integrated Delivery Networks showed lower EHR reporting rates of clinical and disease severity measures, thus compromising the ability of rheumatologists to adopt a guideline-recommended treat-to-target approach in clinical practice. Read More ›

A cardiac MRI follow-up study showed that patients with active rheumatoid arthritis (RA) show myocardial abnormalities at baseline, which significantly improved in patients with early RA following active treatment for 1 year. Read More ›